JUPITER, FL / ACCESSWIRE / September 14, 2020 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company's management will be attending and presenting at the following investor and industry events in September:
H.C. Wainwright 22nd Annual Global Investment Conference
Presenter: Mark Emalfarb
Date: Monday, September 14, 2020
Time: 3:30 PM (EDT)
Webcast: https://wsw.com/webcast/hcw7/dyai/1597167
BPI East
Presenter: Dr. Ronen Tchelet
Date: Tuesday, September 22, 2020
Time: 10:10 AM (EDT)
Event Link: https://informaconnect.com/bioprocessinternational/
Sidoti & Company Conference
Presenter: Mark Emalfarb
Date: Wednesday, September 23, 2020
Time: 1:45 PM (EDT)
Webcast: To be available on the upcoming events on the homepage of the Company's website https://www.dyadic.com
World Vaccine Congress
Event Link: https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
Presenter: Mark Emalfarb
Tuesday, September 29, 2020 at 2:10 PM (EDT)
Title: Novel Industrially Proven Hyper Productive C1 Expression System for Biotherapeutics such as Vaccines & Antibodies
Tuesday, September 29, 2020 at 4:50 PM (EDT)
Title: How do you meet the demand of low-cost manufacturing using new vaccine modalities?
Presenter: Dr. Ronen Tchelet
Wednesday, September 30, 2020 at 4:20 PM (EDT)
Title: Novel Recombinant Influenza Platform - C1 Gene Expression Platform / Speeding the Development, Lowering the Cost & Improving the Performance of Flu Vaccines
Thursday, October 1, 2020 at 3:05 PM (EDT)
Title: Accelerating Development, Lowering Costs and Improving the Performance of Recombinant Vaccines, Antigens & Vlp's
Dyadic Management will be available during the events for one-one-one meetings. Interested investors and industry partners may request a one-on-one meeting at [email protected] or contact Dyadic at (561) 743-8333. If you are registered for any of the events, you can also request a meeting through the event platform.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic's website at http://www.dyadic.com/ for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.
Contact:
Dyadic International, Inc.
Mark Emalfarb
Phone: (561) 743-8333
Email: [email protected]
SOURCE: Dyadic International, Inc.